Journal
DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume 38, Issue 1, Pages -Publisher
WILEY
DOI: 10.1002/dmrr.3505
Keywords
autoimmunity; comorbidity; COVID-19; multiple sclerosis; SARS-CoV-2 infection; type 1 diabetes
Categories
Ask authors/readers for more resources
Multiple sclerosis (MS) and type 1 diabetes (T1D) are chronic conditions stemming from immune system dysfunction, with differences in genetic susceptibility, age of onset, and treatment approaches.
Multiple sclerosis (MS) and type 1 diabetes (T1D) are chronic conditions that result from dysfunction of the immune system. Their common root in autoimmunity stimulates interest in the exploration of similarities and differences between the two diseases. Genetic susceptibility is relevant, creating a substrate, on which environmental factors act as a trigger of an aberrant immune response. Despite being both T-cell mediated disorders with a strong involvement of the humoral arm, immunomodulation is a mainstay of MS management, whereas hormone replacement therapy remains the principal approach for T1D. T1D is usually diagnosed in children and adolescents, while MS is typical of young adults. This difference has implications for disease progression and treatment. The SARS-CoV-2 pandemic and its effect on immunity may affect the prevalence of these conditions, as well as their clinical manifestation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available